According to the U.S. Judicial Panel on Multidistrict Litigation there are 1,624 lawsuits in the Taxotere multidistrict litigation (MDL) pending against the drug’s manufacturer and French drugmaker Sanofi Aventis (Sanofi). The cases are consolidated in the U.S. District Court of the Eastern District for Louisiana with Judge Kurt D. Engelhardt presiding.
Last month, Judge Engelhardt issued an order establishing the dates of four bellwether trials for the MDL, beginning in January 2019. The initial dates for the other three trials are set for April 8, July 15, and Nov. 4, 2019.
The MDL is moving ahead despite Sanofi’s continued attempts, Reuters reports, to get the claims tossed out of court.
Taxotere is a chemotherapy drug approved by the Food and Drug Administration (FDA) to treat breast cancer and other forms of cancer. And, as Beasley Allen previously reported, it is two times as potent as its safer and just as effective alternative, Taxol. Many patients who took the drug are now experiencing permanent hair loss, but were never warned of the risk. Unlike Taxol, Taxotere can destroy hair follicles, preventing hair from growing back after treatment.
Although Sanofi knew about the risk and warned patients outside of the U.S. as early as 2005, it refused to warn U.S. patients until 2013 when the FDA demanded the drugmaker change its label and warn patients of the risk of permanent hair loss. Patients suffering from the unnecessary side effect have a permanent physical reminder of their cancer and its impact on their lives.
* * *
Lawyers at Beasley Allen are currently investigating potential cases involving individuals who have suffered permanent hair loss following chemotherapy with Taxotere. For more information on this subject, contact Beau Darley or Melissa Prickett, lawyers in our firm’s Mass Torts Section, at 800-898-2034 or by email at Beau.Darley@beasleyallen.com or Melissa.Prickett@beasleyallen.com.
U.S. Judicial Panel on Multidistrict Litigation
U.S. District Court Eastern District of Louisiana
Jere Beasley Report (March 2017)